The first medication used to treat psychosis associated with Parkinson’s disease was recently approved by the United States Food and Drug Administration. It is called Nuplazid (pimavanserin). Parkinson’s disease is a condition of the nervous system that is characterized by tremors and shaking. It is reported that a psychosis can occur in as many as half of those who suffer from Parkinson’s. Those affected have been reported to see images or hear voices that are not there, which is called a hallucination. They may also passionately believe in an idea that is not truly happening, which is called a delusion.
The safety and efficacy of Nuplazid was demonstrated in a sixteen week clinical trial with close to two hundred individuals. Compared to a sugar pill, Nuplazid reduced hallucinations and delusions and did not worsen symptoms such as tremors.